Antibiotic stewardship programmes, which are a set of interventions aiming at prescribing antibiotics appropriately and responsibly, are one of the key strategies to tackle the current worldwide bacterial resistance crisis. We will present here some examples of international and national initiatives, with a focus on Europe, discuss the role of clinical microbiologists, and present some perspectives and future developments.
Antibiotic stewardship (ABS) is one of the key strategies to tackle the current worldwide bacterial resistance crisis (https:// ec.europa.eu/health/amr/sites/amr/files/amr action plan 2017 en.pdf). It refers to a set of interventions aiming at prescribing antibiotics appropriately and responsibly, even though its precise definition is still a topic of debate Mendelson et al. 2017) .
This commentary will focus on ABS in human medicine, but we acknowledge the importance of a One Health approach, including veterinary medicine, agriculture and the environment.
ABS HAS GAINED POLITICAL ATTENTION
ABS and the broader concepts of antimicrobial stewardship and antimicrobial resistance (AMS and AMR) have gained considerable political attention lately. All Members States present at the 2015 World Health Assembly committed themselves to have national action plans against AMR ready for 2017, with the World Health Organisation (WHO) reporting on the progress of these plans in 2017 (http://www.who.int/ antimicrobial-resistance/global-action-plan/database/en/). AMR was presented as an international priority at the General Assembly of the United Nations in September 2016 (http:// www.un.org/pga/71/2016/09/21/press-release-hl-meeting-onantimicrobial-resistance/), and also at the G20 in July 2017 (http://www.oecd.org/about/secretary-general/g20-healthministers-meeting-fighting-antimicrobial-resistance.htm). The European Commission released its second action plan against AMR in June 2017 (https://ec.europa.eu/health/amr/sites/amr/ files/amr action plan 2017 en.pdf). There is undoubtedly a political momentum, and much efforts should be made not to lose it. The CARA (Conscience of Antimicrobial Resistance Accountability) initiative has been created for that purpose; it is an alliance of organisations, which will collect and collate data on global AMR indicators and report back to the public and United Nations institutions every 2 years (https://cddep.org/blog/ posts/cara conscience antimicrobial resistance accountability and next big thing cddep).
ABS AT THE EUROPEAN LEVEL
At the European level, many initiatives have been implemented but only a few are presented here. The European Commission (Pulcini 2017 ) and several research projects (Dyar et al. 2016 Dyar, Tebano and Pulcini 2017; Howard et al. 2017; Pulcini et al. 2017a,b,c,d,e) . Finally, the E-Bug programme offers open-access educational resources to teach children and teenagers about microbes, antibiotics, hygiene and vaccination at school (http://www.e-bug.eu).
INNOVATIVE ABS STRATEGIES IN EUROPEAN COUNTRIES
Many European countries have implemented ABS programmes at national or regional level. Table 1 presents a small selection of innovative strategies. A recent report gives some update about their progress in the EU (https://ec.europa.eu/health/ amr/sites/amr/files/amr projects 3rd-report-councilrecprudent. pdf). A review of public awareness campaigns has also been recently published (http://www.who.int/selection medicines/ committees/expert/21/applications/s6 antibiotic awareness campaigns.pdf).
THE CRUCIAL ROLE OF CLINICAL MICROBIOLOGISTS IN ABS PROGRAMMES
Clinical microbiologists are key actors of ABS programmes. According to the EU guidelines on prudent use of antimicrobials (https://ec.europa.eu/health/amr/sites/amr/files/amr guidelines prudent use en.pdf), they should:
(i) Ensure that susceptibility testing and reporting are in accordance with treatment guidelines (selective reporting) and European (i.e. EUCAST) and national standards. Ensure timely diagnosis and communication of critical results (e.g. blood cultures). (ii) Provide facility-specific cumulative susceptibility reports for common bacterial pathogens against antibiotics that are recommended in the guidelines. (iii) Be available to clinicians for counselling on diagnostics of infectious diseases, including correct sampling and interpretation of test results, difficult-to-treat pathogens and complicated infections. (iv) As full members of the AMS team, take on responsibilities that include coordination, planning, post-prescription review and feedback.
Special attention should be paid to the way results are reported to clinicians. By modifying the report, clinical microbiologists can greatly influence antibiotic prescribing, as with selective reporting (Pulcini et al. 2017b) . In a recent ESCMID survey conducted in 36 European countries, selective reporting was however in place in only 11 of the countries (Pulcini et al. 2017b) . Moreover, clinical microbiologists should discuss with ABS team members and educate clinicians about the new rapid diagnostic techniques they are implementing in their laboratory, if they want these techniques to be correctly used, in order to have a positive impact on infection management.
PERSPECTIVES AND CONCLUSION
So, much is happening, but so far, bacterial resistance is still a critical issue in Europe. Why is that?
As far as ABS is concerned, ABS programmes have not been fully implemented in all European countries, far from it. No funding has been made available to create ABS teams in all settings (primary care, nursing homes and hospitals), and they are currently non-existent or understaffed at best (Pulcini et al. 2017e) . We need to give as much priority to funding of ABS teams as to research and development of new antibiotics or new diagnostics. Preserving access to existing antibiotics should also be made a priority. First-line essential antibiotics are often not marketed or not available due to shortages in many European countries, and this leads to increased use of second-line antibiotics, which are often broad spectrum and at higher risk of bacterial resistance (Pulcini et al. 2017a,d) .
We probably need to have a broader perspective, and to involve new health professionals in ABS programmes (nurses, community pharmacists, primary care doctors and so on). Informing, educating and engaging the public and all health professionals is also critical.
Finally, changing the system is sometimes less difficult and has a much more powerful impact compared to targeting individuals (Dyar, Tebano and Pulcini 2017) . Thinking outside the box and sharing experiences at regional, national and international level is definitely the way forward.
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